Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin M. Watts, MD, Tara Lin, MD, Eunice S. Wang, MD, Alice S. Mims, MD, Elizabeth H. Cull, MD, Prapti A. Patel, MD, Paul J. Shami, MD, Roland B. Walter, MDPhDMS, Christopher R. Cogle, Ruth A. Chenault, MS, Bret Macpherson, MSc, MBA, Allison Given Chunyk, Catherine J. McMahan, Jane A. Gross, PhD, Scott Stromatt, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141619

Published: 2020

Journal Articles

Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Tara Lin, MD, Geoffrey L Uy, MD, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet, MD

Blood (2020) 136 (Supplement 1): 55–56.

https://doi.org/10.1182/blood-2020-136871

Published: 2020

Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137685

Published: 2020

Journal Articles

Outcomes of HMA and Venetoclax in Relapsed AML Post-Allogenic Hematopoietic Stem Cell Transplant

Osama Diab, MD, Haitham Abdelhakim, MD, Joseph P. McGuirk, DO, Tara Lin, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-141715

Published: 2020

Journal Articles

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Geoffrey L Uy, MD, Laura F. Newell, MD, Tara Lin, MD, Stuart L. Goldberg, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-136882

Published: 2020

Journal Articles

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Dries Deeren, MD PhD, Johan A. Maertens, MD PhD, Tara Lin, MD, Yves Beguin, MD PhD, Benjamin Demoulin, PhD, Martina Fontaine, PhD, Panagiota A. Sotiropoulou, PhD, Erik Alcantar-Orozco, MD, Eytan Breman, Marie-Sophie Dheur, PhD PharmD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD, Frédéric F. Lehmann, MD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-139667

Published: 2020

Journal Articles

V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia

Tara Lin, MD, Gabriel N. Mannis, MD, Harry P. Erba, Mark Levis, MD PhD, Heng Zou, Stefan Faderl, Ronald S. Cheung, Vinod A. Pullarkat, MD

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-136868

Published: 2020

Journal Articles

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

Blood (2020) 136 (Supplement 1): 27–30.

https://doi.org/10.1182/blood-2020-143265

Published: 2020

Journal Articles

Hyperbaric Oxygen Therapy Improves Post-Transplant Umbilical Cord Blood Engraftment

Omar S. Aljitawi, MD, Xiao Yinghua, Tara Lin, MD, Jeff Eskew, PhD, Nikhil Parelkar, Megan Swink, Jeff Radel, PhD, Joseph McGuirk, DO, Linheng Li, PhD, George Vielhauer, Pharm D, PhD

Blood (2012) 120 (21): 4663.

https://doi.org/10.1182/blood.V120.21.4663.4663

Published: 2012

Journal Articles

Propylene Glycol-Free Melphalan Induces Higher Remission Rates in Multiple Myeloma Patients Undergoing Autologous Transplantation

Omar S. Aljitawi, MD, Anna Ludlow, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Tara Lin, MD, J.D Pipkin, PhD, Joseph McGuirk, DO

Blood (2012) 120 (21): 4551.

https://doi.org/10.1182/blood.V120.21.4551.4551

Published: 2012

Journal Articles

Hedgehog Signaling in Normal and Malignant Hematopoiesis.

Akil A. Merchant, MD, Giselle A. Joseph, BS, Evan Jones, BA, Tara Lin, MD, B. Doug Smith, MD, Micheal McDevitt, MD, PhD, Judith E. Karp, MD, Craig Peacock, PhD, David N. Watkins, MBBS, PhD, William H. Matsui, MD

Blood (2007) 110 (11): 3381.

https://doi.org/10.1182/blood.V110.11.3381.3381

Published: 2007

NARROW

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Outcomes of HMA and Venetoclax in Relapsed AML Post-Allogenic Hematopoietic Stem Cell Transplant

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

Hyperbaric Oxygen Therapy Improves Post-Transplant Umbilical Cord Blood Engraftment

Propylene Glycol-Free Melphalan Induces Higher Remission Rates in Multiple Myeloma Patients Undergoing Autologous Transplantation

Hedgehog Signaling in Normal and Malignant Hematopoiesis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only